Please login to the form below

Not currently logged in
Email:
Password:

GSK submits two new flu vaccines for regulatory approval

Seeks licences for quadrivalent influenza vaccine and pandemic influenza vaccine

GlaxoSmithKline (GSK) has filed two new influenza vaccines for regulatory approval.

Its quadrivalent influenza vaccine, which has yet to be approved in its first market, has been submitted to the US Food and Drug Adminstration (FDA) and the European Medicines Agency (EMA).

GSK is seeking approval for the vaccine to be used in adults and children from three years of age against influenza disease caused by influenza virus types A and B that are contained in the vaccine.

The pharma company submitted a supplemental Biologics License Application to the FDA and filed a new application to the EMA.

Pandemic flu vaccine

Meanwhile, GSK has also submitted its H5N1 pandemic flu vaccine to the FDA for use in adults “as directed by the US Government”.

GSK's H5N1 influenza vaccine programme was supported by a development contract with the Biomedical Advanced Development and Research Authority (BARDA) of the US Department of Health and Human Services.

That vaccine was approved in March, 2011 in Europe, where it is marketed under the brand name Pumarix and GSK's biologics unit has a five-year marketing authorisation from the European Commission.

6th March 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Gower Publishing Limited

Gower is recognised as one of the world's leading publishers of specialist business and management books and resources. Our publishing...

Latest intelligence

14_ipad_lowres.jpg
Do your customers feel that you’re listening to them?
When answering to data, excellent digital communication can create much stronger relationships between reps and customers....
Mapping content strategies to pharma lifecycle management
In these tough economic times, we should be ramping up our pharma lifecycle management (LCM) strategies. These are well-established strategies for managing and extending the commercial value of products. So...
Back from the future – innovation for pharma
After 5 days of seeing amazing innovations, having discussions about the future of medicine and the practicalities of living on Mars. Plus listening to inspiring speakers from fighter plane-flying physicians...

Infographics